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Abstract
We have previously identified a tyrosine kinase-independent, guanine nucleotide exchange factor
(GEF) activity that is contained within the region of p210 BCR/ABL that distinguishes it from
p190 BCR/ABL. In the current study we have compared the transforming activity of p190 BCR/
ABL, p210 BCR/ABL, and a mutant that lacks GEF activity (p210 BCR/ABL(S509A)). In cell-
based, ex vivo, and murine bone marrow transplantation assays (BMT) the transforming activity of
p210 BCR/ABL(S509A) mimics p190 BCR/ABL, and is distinct from p210 BCR/ABL. Thus, in
the BMT assay, the p190 BCR/ABL and p210 BCR/ABL(S509A) transplanted mice exhibit a
more rapid onset of disease than mice transplanted with p210 BCR/ABL. The reduced disease
latency is associated with erythroid hyperplasia in the absence of anemia, and expansion of the
MEP, CMP and GMP populations, producing a phenotype that is similar to acute myeloid
leukemia (AML-M6). The disease phenotype is readily transplantable into secondary recipients.
This is consistent with ex vivo clonogenicity assays where p210 BCR/ABL preferentially supports
the growth of CFU-GM, while p190 BCR/ABL and the mutant preferentially support the growth
of BFU-E. These results suggest that the GEF activity that distinguishes p210 BCR/ABL from
p190 BCR/ABL actively regulates disease progression.
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Introduction
The Philadelphia chromosome results from a translocation that joins sequences from the
BCR gene located on chromosome 22, with sequences from the ABL gene located on
chromosome 9 (1, 2). Depending upon the location of the breakpoint within BCR, three
different forms of the BCR/ABL fusion protein can be produced: p190 BCR/ABL, p210
BCR/ABL, and p230 BCR/ABL. Although all three fusion products are associated with
leukemia, the clinical outcomes are discrete (1). p210 BCR/ABL is the most common
variant and is causally associated with virtually all cases of CML; p190 BCR/ABL is found
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tin approximately 25% of ALL; and p230 BCR/ABL has been observed in a subset of the
chronic neutrophilic leukemias (3). In all cases the leukemia is dependent upon a
constitutive tyrosine kinase activity that resides within the ABL sequences. Since the
difference in the three BCR/ABL variants lies within the contributions from BCR, it seems
likely that activities that reside within BCR may also contribute to disease progression.
Consistent with this, cell- and animal-based studies have identified BCR sequences that are
either required to support the tyrosine kinase activity (4–6), or are substrates for this activity
(7). However, since all these activities lie within regions of BCR that are retained in all the
fusion variants, they cannot account for the variant-specific disease outcome.
Residues 426-927 of BCR are of particular interest since they are contained within p210
BCR/ABL, but not p190 BCR/ABL. Whether or not the strong association of p190, and
p210 BCR/ABL with ALL and CML, respectively, reflects the influence of these residues
on leukemogenic activity, or simply reflects the innate tendency of hematopoeitic lineages to
form specific rearrangements, remains unsettled. It is possible that these sequences may
represent an inert spacer that regulates ABL-encoded tyrosine kinase activity by modulating
the interaction between amino-terminal sequences of BCR and regulatory sequences within
ABL(4, 8). It has been reported that p190 BCR/ABL has greater intrinsic tyrosine kinase
activity than p210 BCR/ABL, although several studies suggest that this difference may be
modest (9–11). Contained within residues 426-927 of BCR are tandem Dbl homology (DH)
and pleckstrin homology (PH) domains that are characteristic of RhoGEF family members
(12). Two recent studies indicate that this domain is active, and utilizes RhoA as a substrate
in the context of p210 BCR/ABL (13, 14). p210 BCR/ABL can activate RhoA in cell-based
assays, while p190 BCR/ABL cannot (15), and the introduction of mutations into the DH
domain of p210 BCR/ABL that are predicted to eliminate the RhoGEF activity inhibit its
ability to activate RhoA (13, 14). Whether or not this domain contributes to disease
progression has not yet been determined.
The murine BMT model for CML provides an experimental system that allows direct
comparisons of the disease phenotype that arises from specifically mutated versions of p210
BCR/ABL. Although p190 BCR/ABL and p210 BCR/ABL are able to induce a
myeloproliferative-like disorder in this model, p190-BCR/ABL does so with a shorter
latency (9, 10, 16). In the current study we compare the transforming activity of p190 BCR/
ABL, p210 BCR/ABL, and a p210 BCR/ABL mutant that lacks RhoGEF activity. In both
cell- and animal-based models, p190 BCR/ABL and the RhoGEF mutant of p210 BCR/ABL
have virtually identical transforming activity, which is distinct from p210 BCR/ABL. Thus,
whereas p210 BCR/ABL predominantly induces myeloid leukemias in the murine BMT
model, p190 BCR/ABL and the mutant induce mixed myeloid/erythroid leukemias which
are associated with a reduced disease latency. These results support a model in which the
GEF activity that distinguishes p210 BCR/ABL from p190 BCR/ABL actively regulates
disease progression by influencing lineage-specific leukemic expansion.
Materials and methods
Molecular constructs and cell culture
The MSCV-IRES-gfp (MIG) retroviral vector has been previously described (Addgene,
Cambridge, MA) (17). MSCV-bcr-abl/p190-IRES-gfp, MSCV-bcr-abl/p210-IRES-gfp and
MSCV-bcr-abl/p210(S509A)-IRES-gfp contain full-length p190 BCR/ABL, p210 BCR/
ABL, and a p210 BCR/ABL RhoGEF mutant respectively (14). Phoenix-Ecotropic cells
(ATCC, Manhassas, VA) were maintained in DMEM supplemented with 10% FBS
(Gemini, Woodland, CA). Ba/F3 cells were cultured in RPMI supplemented with 10% FBS
and IL-3-conditioned WEHI media. High titer retrovirus was generated using Phoenix-
Ecotropic packaging cells as previously described (14).
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tProtein expression
Western blot analysis was performed as previously described (18). Antibodies used include:
anti-Bcr (N20), anti-RhoA (26C4), anti-MLC2 (Fl-172) (Santa Cruz, Santa Cruz, CA); anti-
phospho-MLC2(Ser19) (Cell Signaling, Danvers, MA). Affinity purification assays to
measure the levels of endogenous GTP-bound RhoA were performed using Rhotekin-RBD
Protein GST beads (Cytoskeleton, Denver, CO) as previously described (19).
Cell proliferation and apoptosis assays
Ba/F3 cells were infected by retroviral particles that encode MSCV-bcr-abl/p210-IRES-gfp,
MSCV-bcr-abl/p210(S509A)-IRES-gfp, MSCV-bcr-abl/p190-IRES-gfp, or cognate vector.
At 48 hr post-infection cells that express GFP were sorted by FACS, seeded in media with
and without IL-3, and then grown for 24, 48 and 72 hr time points. For proliferation assays
cells were counted using a hemacytometer. For cell cycle analysis cells were washed with
PBS, fixed with ethanol for 20 minutes, then resuspended in PI-RNase solution (50μg/ml PI
+ 100μg/ml RNase A in PBS), incubated for another 20 minutes, and analyzed by flow
cytometry. Quantification of apoptotic cells was performed using the Annexin V-Biotin
Apoptosis Detection Kit according to the manufacturer's instructions (Calbiochem, La Jolla,
CA). All experiments were performed on a minimum of three independent sorts.
Animals
BALB/c mice used in these studies were housed under pathogen-free conditions. All animal
care, housing, and experimentation was conducted in accordance with protocols approved by
the Institutional Animal Care and Use Committee of UMDNJ-New Jersey Medical School.
Bone marrow transduction
Retroviral transduction of bone marrow was done as previously described (20). Briefly,
bone marrow cells were harvested and an enriched stem cell/mononuclear cell fraction was
purified via Ficoll separation (Histopaque-1083; Sigma, St. Louis, MO). If cells were to be
used for transplantations the mice were injected with 3.0 mg 5-Fluorouracil 6 days prior to
harvesting. Prior to retroviral transduction, cells (2 × 106/ml) were prestimulated for 48
hours in IDMEM containing 10% Premium FBS (Atlanta Biologicals, Lawrenceville, GA),
2% Penicillin/Streptomycin, and 100 ng/ml each of recombinant murine TPO, G-CSF, and
SCF (Peprotech, Rocky Hill, NJ). For primary transduction, cells were resuspended in
appropriate retroviral supernatant containing growth factors and seeded onto fibronectin
coated wells ((21); Retronectin; Takara Bio, Otsu, Japan). After 24 hours incubation, cells
were resuspended in fresh retroviral supernatant and incubated for an additional 48 hours.
GFP positive cells were then sorted by FACS (FACSDiVA, BD Biosciences, Franklin
Lakes, NJ).
Ex vivo analysis of murine hematopoietic progenitor cells
GFP sorted primary bone marrow cells were serially diluted in triplicate in 24-well plates in
Whitlock-Witte media (RPMI supplemented with 5% FBS, 200 μM L-glutamine, 50 μM 2-
mercaptoethanol and penicillin-streptomycin). Cells were cultured for 3 weeks and were
scored as positive for transformation when the number of cell exceeded 1×106 cells per ml
of medium. MethoCult GF M3434 and M3630 (StemCell Technologies, Vancouver,
Canada) was used to detect and quantify mouse hematopoietic progenitors in bone marrow
following the manufacturer's instructions. To confirm the identity of colonies, cells were
dissociated and stained with Hema 3.
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For bone marrow transplantations both GFP positive and negative cells were sorted by
FACS (FACSDiVA, BD Biosciences, Franklin Lakes, NJ). Transplantations were performed
by injecting 5.0 × 104 GFP positive cells and 3.5 × 105 GFP negative cells into the tail vein
of recipient BALB/c mice that had been lethally irradiated with a split dose of 900 rads
(Mark I irradiator (model 68A), J.L. Shepherd and Associates). For secondary
transplantations, a total of 1×106 cells (5×105 bone marrow cells and 5×105 spleen cells)
from diseased mice were injected into the tail veins of sublethally (450rad) irradiated
BALB/c mice.
Evaluation of disease progression by flow cytometry
Mice were euthanized through CO2 inhalation, and hematopoietic organs were harvested.
Antibodies used for staining were CD11b(Mac-1)-PE, CD45R/B220-APC, CD3e-PerCP-
Cy5.5, CD71-PE, Ter119-APC and CD117-PerCP-Cy5.5 (BD Biosciences, Franklin Lakes,
NJ). Flow cytometry analysis was performed on a FACSCalibur using CellQuest software
(BD Biosciences, Franklin Lakes, NJ).
Histopathology
Peripheral blood smears were made with blood obtained from tail-vein puncture, and
staining was performed using Hema 3 solutions (Fisher Scientific, Pittsburgh, PA). Solid
organs were harvested and fixed in 10% neutral buffered formalin (Sigma, St. Louis, MI)
prior to paraffin sectioning. Five micron sections were then stained with hematoxylin and
eosin. Complete blood cell counts were performed on heparinized blood obtained through
cardiac puncture. Manual counts were conducted using a hemacytometer and automated
counts were conducted by Antech Diagnostics (Lake Success, NY).
Progenitor analysis by flow cytometry
Bone marrow cells were harvested at death and stained with biotinylated antibodies specific
for the following lineage markers: CD45R (B220), Cd11b, CD8a, CD4, CD3e, Ter-119,
Gr-1 and IL-7Rα (eBioscience, San Diego, CA), incubated for 30 min, then washed and
stained with the following additional markers: PE-Texas Red-Streptavidin, APC-Cy7-Sca-1,
Brilliant Violet 421-CD117, (BioLegend, San Diego, CA), PE-CD34 and PE-Cy7-CD16/
CD32 (BD Biosciences, Franklin Lakes, NJ). FACS analysis was performed using the BD
LSR II flow cytometer (BD Biosciences, Franklin Lakes, NJ).
Statistics
Statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad Software).
Data sets in Figure 1, 2 and 4 were analyzed using one-way ANOVA, followed by Student's
t-test. Once the statistical analysis was complete for Figure 2, the data was converted to fold
activations to facilitate ease of comparison. Kaplan-Meier curves were analyzed using a
Log-rank (Mantel-Cox) test.
Results
The RhoGEF activity of p210 BCR/ABL targets RhoA signaling in hematopoietic cells
We have previously shown that the RhoGEF activity of p210 BCR/ABL utilizes RhoA as a
substrate in 293T cells (14). To confirm that it also utilizes RhoA as a substrate in
hematopoietic cells we infected Ba/F3 cells with bicistronic retroviral vectors that encode
p190 BCR/ABL, p210 BCR/ABL, or p210 BCR/ABL(S509A), along with GFP. GFP+ cells
were sorted and then Western blots were performed to confirm equal expression of the
proteins (Figure 1A). Affinity precipitation assays for activated RhoA were then performed
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t(Figure 1B). Although the level of total RhoA is equivalent in all cell lines, the level of
activated RhoA is significantly higher in cells expressing p210 BCR/ABL compared to
vector controls. A small, but significant increase in activated RhoA is also observed in cells
that express p210 BCR/ABL(S509A) but not p190 BCR/ABL. These observations suggest
that although the p210 BCR/ABL(S509A) mutant is substantially impaired in its ability to
activate RhoA, it may retain some residual RhoGEF activity.
Myosin light chain 2 (MLC2) is a component of myosin that is phosphorylated on Ser 19 by
ROCK, the preferred effector molecule for RhoA. To confirm activation of RhoA-mediated
signaling in the transduced cell lines, lysates were examined for levels of phosphorylated
MLC2 (p-MLC2(Ser19)). When compared to vector transduced cells, we observe
significantly elevated levels of p-MLC(Ser19) in cells that express p210 BCR/ABL, but not
in those transduced with p190 BCR/ABL or p210 BCR/ABL(S509A) (Figure 1C). This is
consistent with the RhoA activity assays, and suggests that the mutant is impaired in RhoA
signaling in hematopoietic cells.
The RhoGEF activity of p210 BCR/ABL influences interleukin 3 (IL-3)-dependent and -
independent growth in hematopoietic cells
The Ba/F3 cells that were used to analyze Rho activity were then compared for proliferation
in the presence or absence of IL-3. In the presence of IL-3, cells that express p210 BCR/
ABL grow significantly slower than cells that express cognate vector (Figure 1D). In
contrast, cells that express p190 BCR/ABL or p210 BCR/ABL(S509A) show an equivalent
2-fold increase in growth relative to vector. In the absence of IL-3 the majority of vector
transduced cells are dead by 72h (Figure 1E). As expected, the p210 BCR/ABL transduced
cells are able to proliferate in the absence of IL-3 and achieve a cell density at 72h that is
similar to their density in the presence of IL-3 (5 × 105 /ml vs 4 × 105/ml) (Figure 1E).
Although both the p190 BCR/ABL and p210 BCR/ABL(S509A) transduced cells also
proliferate in the absence of IL-3, they achieve a cell density at 72h that is significantly
lower than the p210 BCR/ABL transduced cells. Thus, although all three constructs were
able to confer IL-3 independent growth, p190 BCR/ABL and p210 BCR/ABL(S509A) did
so to a significantly lesser degree.
Next we determined whether the difference in growth rates of the p210 BCR/ABL and p210
BCR/ABL(S509A) transduced cells in the absence of IL-3 could be attributed to a difference
in their resistance to apoptosis. For this analysis we plated 5-fold more cells than the
proliferation assays in order to more accurately measure apoptosis in the vector transduced
cells. When compared to vector transduced cells, cells that express p210 BCR/ABL are
significantly more resistant to apoptosis at 72 h (45% vs 70% annexin positive at 72h)
(Figure 1F). In contrast cells that express p190 BCR/ABL and p210 BCR/ABL(S509A)
undergo apoptosis at a similar frequency than cells that express vector. Thus, although both
constructs can induce a higher rate of proliferation, they do not provide the survival
advantage provided by p210 BCR/ABL. To confirm these observations the cells were then
stained with PI and a cell cycle analysis was performed (Figure 1G). This analysis
confirmed the increased proportion of cells in sub-G1 for the p190 BCR/ABL and p210
BCR/ABL(S509A) expressing cell lines, and a reduced number of cycling cells. This
difference is apparent by 24 hr post-infection.
RhoGEF activity influences transformation in murine bone marrow ex vivo assays
To explore the role of the RhoGEF domain in the transformation of murine hematopietic
progenitor cells, bone marrow was collected from BALB/C mice and infected with
retrovirus that express p190 BCR/ABL, p210 BCR/ABL, p210 BCR/ABL(S509A), or
cognate vector. Cells were then sorted for GFP expression and plated in Whitlock-Witte
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tmedia at various dilutions in triplicate. p210 BCR/ABL induced rapid outgrowth of cultures
seeded with as few as 1×104 cells while vector expressing cells were transformation
deficient (Figure 2A). The outgrowth of p190 BCR/ABL and p210 BCR/ABL(S509A)
infected cells was observed only at densities of 3×104 or higher, and the number of days
required to reach saturation at this concentration was significantly higher. To determine
whether the constructs also differ in their ability to induce outgrowth of specific lineages
bone marrow colony formation was assessed on media that supports growth of granulocyte-
macrophage progenitors (CFU-GM) and erythroid progenitors (BFU-E) (M3434), and on
media that supports growth of B cell progenitor cells (CFU-preB) (M3630). When we
compared p210 BCR/ABL to vector on the M3434 media, we observed an equivalent
number of BFU-E colonies (Figure 2B), but a significant increase in CFU-GM colonies on
the p210 BCR/ABL plates (Figure 2C). In contrast, when we compared p190 BCR/ABL, or
the p210 BCR/ABL(S509A) mutant, to vector on the same media, we observed significantly
fewer CFU-GM colonies (Figure 2C) and significantly more BFU-E colonies (Figure 2B).
Thus, when grown on media that supports the growth of both BFU-E and CFU-GM, p210
BCR/ABL favors CFU-GM expansion, while p190 BCR/ABL and the mutant favor BFU-E
expansion. In the CFU-preB cell assay all three constructs exhibited a similar, high level of
transformation (Figure 3D). To confirm the identity of the colonies induced by the
constructs, cells were dissociated from randomly chosen colonies and stained with Hema 3.
As expected, the BFU-E colonies are comprised of reticulocytes and nucleated red blood
cells, the CFU-GM colonies are comprised of myeloid precursors, and the CFU-pre-B
colonies are comprised of lymphoid precursors (Figure 2B–D, right panels).
RhoGEF activity contributes to disease progression in a bone marrow transplantation
(BMT) model for CML
To examine the role of the RhoGEF domain in vivo we determined whether it contributes to
disease progression in the murine bone marrow transplantation model for CML. Consistent
with previous studies (10, 17, 22), all p210 BCR/ABL transplanted mice (3 independent
experiments, n = 20 total) become moribund within 23–38 days of transplantation displaying
cachexia, a decrease in activity and increased respirations (Figure 3A, Table 1). WBC
counts taken at death are elevated (Table 1). An examination of peripheral blood smears
prepared when the mice become moribund reveal polychromasia and extensive leukocytosis
with a predominant expansion of myeloblasts and neutrophils (Figure 3B, Table 1). In
contrast, mice transplanted with p190 BCR/ABL or p210 BCR/ABL(S509A) begin to
exhibit signs of overt illness earlier than those transplanted with p210 BCR/ABL (within 12
days of transplantation) and the average lifespan and the range of ages at which the mice
become moribund are significantly shorter (Figure 3A, Table 1). WBC counts are elevated,
and outside the normal range, but 3 fold lower than p210 BCR/ABL transplanted mice at
death. The peripheral blood smears prepared when the mice become moribund also reveal
polychromasia, but a more limited expansion of the myeloid lineage than p210 BCR/ABL
transplanted mice. In addition, large numbers of nucleated red blood cells are observed
(nRBCs; Figure 3B).
All mice were subject to histologic examination. All mice had splenomegaly (Figure 3B and
Table 1) at death and showed disruption of both the white and red pulp by infiltrating
myeloid cells and foci of extramedullary hematopoeisis (Figure 3C). In the liver, myeloid
cells infiltrated both sinusoids and portal tracts. As previously seen in other studies (10, 17,
22), large numbers of myeloid cells were present in pulmonary capillaries, together with
extensive focal hemorrhage and consolidated regions. Despite the similar pathology
associated with the three constructs, the organ architecture was consistently better preserved
at death in mice transplanted with p190 BCR/ABL and p210 BCR/ABL(S509A), and the
spleen size was consistently smaller.
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subject to immunophenotyping (Table 2). Mononuclear cells were collected from peripheral
blood, spleen and bone marrow, and examined for the expression of GFP, myeloid (CD11b),
T cell (CD3), and B cell (B220) markers. At death approximately 86% of WBCs from mice
transplanted with p210 BCR/ABL are GFP+ compared to 53% for p190 BCR/ABL and 49%
for p210 BCR/ABL(S509A) (Table 1). When this is considered along with the lower WBC
counts at death (Table 2), we conclude that the shortened lifespan of the p190 BCR/ABL
and p210 BCR/ABL(S509A) transplanted mice cannot be simply attributed to accelerated
myeloid expansion.
Staining of the mononuclear cells with myeloid and lymphoid specific markers reveals
modest qualitative differences in disease phenotype. For the p210 BCR/ABL transplanted
mice all animals have myeloid leukemias. The p190 BCR/ABL and p210 BCR/
ABL(S509A) transplanted mice also predominantly show myeloid expansion but also,
elevated levels of B and T cells are observed in the marrow and spleen. Overall the disease
phenotype of p190 BCR/ABL and p210 BCR/ABL(S509A) mice are indistinguishable.
To examine the expansion of the erythroid lineage, peripheral blood was collected at death
from additional mice, and CBCs were performed to determine the number of nRBCs,
reticulocytes, and erythrocytes (Table 3). At death the p210 BCR/ABL transplanted mice
have normal total RBC counts, but show a 3 fold increase in reticulocytes relative to vector
transplanted mice, and a small increase in nRBCs. Hemoglobin and hematocrit levels are
relatively normal. The p190 BCR/ABL and p210 BCR/ABL(S509A) transplanted mice also
do not exhibit anemia, and have normal hemoglobin and hematocrit levels. However, they
have even higher reticulocyte counts (6 fold increase), and abnormally high numbers of
circulating nRBCs. To confirm the expansion of the erythroid lineage we stained the
peripheral blood, bone marrow, and spleen of the mice for erythroid markers (Table 3,
CD71+/Ter119+). For this analysis mature RBCs were removed with Ficoll, rather than lysis
buffer, to preserve fragile nRBCs. Although all three constructs show elevated numbers of
CD71+/Ter119+ cells relative to vector, a consistently higher number of cells is observed in
the p190 BCR/ABL and p210 BCR/ABL(S509A) transplanted mice (Table 3).
The elevated numbers of blast cells observed in the blood smears suggests that the p190
BCR/ABL and p210 BCR/ABL(S509A) transplanted mice may be succumbing to more
acute leukemia's than the p210 transplanted mice. To confirm this, peripheral blood, bone
marrow and spleen was collected from randomly selected mice and cells were stained for
CD117 (Table 4), a marker for AML. In all three tissues examined the number of GFP+/
CD117+ cells was slightly increased in the p210 BCR/ABL transplanted mice relative to the
vector transplanted mice. In contrast, the number of GFP+/CD117+ cells was dramatically
increased in the p190 BCR/ABL and p210 BCR/ABL(S509A) transplanted mice suggesting
a more acute phenotype. In order to determine whether a particular progenitor population
was selectively amplified in the p190 BCR/ABL and p210 BCR/ABL(S509A) transplanted
mice, progenitor flow was performed on the bone marrow cells. Our analysis showed that
GMPs, CMPs and MEPs are significantly increased in the p190 BCR/ABL and p210 BCR/
ABL(S509A) transplanted mice relative to the p210 BCR/ABL transplanted mice, but the
greatest increase is observed for the MEPs (Figure 4A and 4B).
In order to confirm that the erythroid expansion observed in the p190 and mutant
transplanted mice is an element of the malignancy, and not a reactive process, secondary
transplantations were performed. Of the five primary tumors examined from the p210 BCR/
ABL transplanted mice two transmitted a myeloproliferative disease with a longer latency
but similar phenotype (Figure 4C). The remaining three developed a B-ALL phenotype with
longer disease latency. For all of the primary tumors examined for the p190 BCR/ABL and
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tp210 BCR/ABL(S509A) transplanted mice it was possible to transmit the erythroleukemia
to the secondary recipients. Thus, in all cases the disease in the secondary recipients closely
resembled the primary erythroleukemic disease, both in phenotype and latency. Collectively
these observations suggest that the p190 BCR/ABL and p210 BCR/ABL(S509A)
transplanted mice succumb to acute erythroid leukemia's similar to M6a in humans. They
further suggest that either the MEPs have acquired self-renewal ability in the p190 BCR/
ABL or mutant transplanted mice, or that the leukemia's are originating from a common
progenitor population that is capable of differentiating via myeloid and erythroid lineages.
Discussion
To directly assess the contribution of RhoGEF activity to p210 BCR/ABL transformation,
we have introduced a single amino acid substitution into the DH domain of p210 BCR/ABL
that impairs RhoGEF activity, without affecting tyrosine kinase activity. When tested in cell,
ex vivo, and animal-based models of transformation this mutant induces a disease phenotype
that is discrete from p210 BCR/ABL, but indistinguishable from p190 BCR/ABL. When
viewed in its entirety, our data suggests that the RhoGEF activity of p210 BCR/ABL
directly contributes to transforming activity, and may account for the difference in disease
outcome associated with p190 BCR/ABL and p210 BCR/ABL.
A comparison of transforming activity in cultured cells reveals that the RhoGEF activity
may have differential effects on both proliferation and survival. Thus, in the presence of
IL-3, cells that express vector, p190 BCR/ABL or the p210 BCR/ABL(S509A) mutant
proliferate more rapidly than those that express p210 BCR/ABL, suggesting that the
RhoGEF activity can be limiting with respect to proliferation. Interestingly, the p190 BCR/
ABL and mutant expressing Ba/F3 cells do not enjoy a substantive survival advantage when
IL-3 is withdrawn, which leads to a disproportionate reduction in proliferative potential
relative to the p210 BCR/ABL expressing cells. Thus, the RhoGEF activity limits
proliferation, but supports survival. The ability of p210 BCR/ABL to provide survival
signaling has been well documented (23). Although survival is thought to be predominantly
mediated by tyrosine kinase-dependent activation of the PI3K/AKT pathway, the
mechanism of activation remains unsettled (23). Current evidence suggests the pathway can
be activated by the GRB2/GAB2 complex which is recruited to Y177 in the BCR sequences
(24), or alternatively, by recruitment and activation of CRKL and CBL (25). p210 BCR/
ABL has also been shown to activate STAT5 which regulates the expression of anti-
apoptotic genes such as MCL-1 and BCL-xL (26, 27). Our current study also implicates
RhoA mediated signaling pathways in p210 BCR/ABL survival signaling. RhoA signaling
has been shown to promote survival in a variety of tissue types (28–31), and was recently
shown to be required for the B cell activating factor-mediated survival response (32).
In the absence of Il-3 there does appear to be a limited population of p190 BCR/ABL and
mutant expressing cells that can evade apoptosis and retain a high proliferative capacity.
This possibility is supported by a previous study which showed that p190 BCR/ABL
transformed BA/F3 cells proliferate more rapidly than p210 BCR/ABL transformed cells in
the absence of IL-3 (10). In this case, the authors used cell lines that had been stably selected
with neomycin, and thus would have negatively selected against cells undergoing apoptosis,
and positively selected for those that retain their high proliferative potential.
Our observation that both p190 BCR/ABL and the p210 BCR/ABL(S509A) mutant are still
able to drive myeloproliferation in the bone marrow transplantation model is consistent with
previous studies which showed that p190 BCR/ABL induces myeloid leukemia's with
reduced latency if the donor mice are pre-treated with 5-FU (9, 10). However, we observed
that myeloid expansion and organ disruption at death was much more limited than in mice
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ttransplanted with p210 BCR/ABL. Instead we observed leukocytosis, coupled with
expansion of nRBCs, and reticulocytosis, suggesting that the leukemic expansion is
qualitatively different. An examination of lineage specific markers and progenitor analysis
confirmed the presence of elevated numbers of GMPs, CMPs and MEPs consistent with
acute erythroleukemia (AML-M6) and is likely to account for the reduced disease latency
associated with the transplanted mice. These tumors are readily transplantable into
secondary recipients suggesting that they arise from a common progenitor population that is
capable of differentiating via myeloid and erythroid lineages. Although previous studies
have not noted the erythroid expansion (9, 10), these studies did not indicate that CBCs were
performed, or that erythroid markers were examined. Thus, the phenotype may have been
present, but not noticed.
The enhanced ability of p190 BCR/ABL and p210 BCR/ABL(S509A) to drive expansion of
the erythroid lineage was further confirmed by their ability to induce BFU-Es in colony
forming assays. It has been shown previously that when grown in media that allows
detection of CFU-GM alone, both p190 BCR/ABL and p210 BCR/ABL support the growth
of CFU-GM colonies (9). However, when we cultured bone marrow cells in the presence of
media that allows detection of both BFU-E and CFU-GM, we observed that p210 BCR/ABL
preferentially supports the growth of CFU-GM, while p190 BCR/ABL and the mutant
preferentially support the growth of BFU-E. This suggests that the RhoGEF domain both
actively supports myeloid expansion, and limits erythroid expansion. The former possibility
is supported by a recent study in which an inhibitor of the RhoA/ROCK complex was shown
to oppose the proliferation of human CML CD34+ cells (33).
BCR/ABL rearrangements are found in 1–3% of cases of AML (including AML-M6) (34–
37), and cases of erythroleukemic blast crisis have been described in CML (38). Since
transition to blast crisis is generally thought to be triggered by the acquisition of secondary
mutations, our results suggest that loss of Rho signaling in the leukemic stem cell that
occurs secondary to p210 BCR/ABL transformation, may be sufficient to switch the fate of
these cells from myeloid expansion to erythroid expansion, and account for these
erythroleukemic blasts.
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tFigure 1.
The RhoGEF activity of p210 BCR/ABL regulates RhoA and influences IL-3 dependent and
independent growth in hematopoietic cells. Ba/F3 cells were infected with retroviral
particles that encode MSCV-bcr-abl/p210-IRES-gfp, MSCV-bcr-abl/p210(S509A)-IRES-
gfp, MSCV-bcr-abl/p190-IRES-gfp, or cognate vector. (A–C) GFP-positive cells were
sorted, and then plated for 48 hr. (A) Lysates were collected and examined by Western blot
for expression of the Bcr-Abl constructs. (B) Lysates were also examined by affinity
precipitation assays to measure levels of total (RhoA) and activated (GTP-RhoA) RhoA, and
(C) by Western blot for levels of total (MLC2) and phosphorylated (p-MLC2(Ser19))
myosin light chain 2. (A–C) All Western blots were performed in triplicate and quantitated
using Quantity One software (BioRad). Quantitated data shown are derived from three
independent sorts, and show standard deviations, and statistical significance relative to MIG
vector controls (B and C). (D–G) GFP-positive cells from the same sorts were immediately
plated in the presence (D) or absence (E, F & G) of IL-3. (D&E) Cells were counted at the
indicated time points. (F) The percentage of apoptotic cells was determined at the indicated
time points. (G) The percentage of cells in Sub-G1, G1, S and G2/M cell cycle phases was
determined at indicated time points. (A–G) Data shown are an average of three independent
experiments performed on three independent sorts and show standard deviations, and
statistical significance as indicated (* p < 0.05, ** p < 0.01, *** p < 0.001).
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Loss of RhoGEF activity alters the transforming potential of p210 BCR/ABL in murine ex
vivo assays. Bone marrow was collected from BALB/c mice and infected with retroviral
particles that encode MSCV-bcr-abl/p210-IRES-gfp, MSCV-bcr-abl/p210(S509A)-IRES-
gfp, MSCV-bcr-abl/p190-IRES-gfp, or cognate vector. (A) GFP positive cells were
collected and plated at the indicated cell numbers per well and in the absence of cytokines.
Assays were performed in triplicate. A well was scored positive when the number of viable
cells reached 106/well. Cell growth was monitored for 21 days. (B) GFP positive cells were
collected and plated in MethoCult media that supports the growth of both BFU-E and CFU-
GM (B & C), or CFU-pre-B (D). Colonies were counted and expressed as fold change
relative to p210 BCR/ABL. Data shown is the average of three independent experiments and
shows standard deviations, and statistical significance relative to p210 (* p < 0.05, ** p <
0.01, *** p < 0.001). Cells were dissociated from random colonies and stained with Hema 3
to confirm the identity of the colonies. Right panels show a representative colony and the
staining of the dissociated cells. Images of colonies were visualized using an Advanced
Microscopy Group microscope; EVOS (Bothell, WA, USA) at 4×PH magnification using
Micron(EVOS) 2.0 software. Images of cells from colonies were visualized under oil using a
Carl Zeiss microscope; Zeiss Axio Imager A1 (Thornword, NY, USA) equipped with
ACHROPLAN, 100x, 1.25 numerical aperture, and acquired using AxioCam MRC camera
and Axiovision 4.7.1 software.
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Altered disease progression in mice transplanted with the p210 BCR/ABL(S509A) mutant.
Bone marrow was collected from BALB/c mice and infected with retroviral particles that
encode MSCV-bcr-abl/p210-IRES-gfp, MSCV-bcr-abl/p210(S509A)-IRES-gfp, MSCV-bcr-
abl/p190-IRES-gfp, or cognate vector. GFP positive cells were collected and used for the
bone marrow transplantation assay. (A) Survival curves for recipient mice transplanted with
vector, p190 BCR/ABL, p210 BCR/ABL or p210 BCR/ABL(S509A). Kaplan-Meier curves
were generated for three independent experiments. BMT = bone marrow transplantation.
When comparing p210 BCR/ABL with p210 BCR/ABL(S509A), Mantel-Cox tests of the
three survival curves yielded values of p = 0.0011 (χ2 = 10.73), p = 0.0013 (χ2 = 10.38) and
p < 0.0001, (χ2 = 16.35) respectively. (B) Blood smears were performed weekly on the mice
to monitor disease progression. The representative smears, and spleens, shown were taken
when mice became moribund except p210 (day 14) which was done on day 14 post-BMT.
Black arrows indicate nucleated red blood cells. (C) Spleen, liver, and lung tissues were also
harvested at the time of death, and processed slides were stained with hematoxylin and
eosin. Images of blood smears were visualized under oil using a Carl Zeiss microscope;
Zeiss Axio Imager A1 (Thornword, NY, USA) equipped with ACHROPLAN, 100x, 1.25
numeical aperture, and acquired using AxioCam MRC camera and Axiovision 4.7.1
software. Images of solid organs were visualized with the same microscope using Ec Plan-
NEOPLUAR 10x, 0.3 numerical aperture.
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The RhoGEF activity of BCR/ABL limits the self-renewal of myeloid progenitors in the
BMT model. Bone marrow cells isolated from diseased mice at death were used for
immunophenotypic analysis of progenitor populations. (A) Representative FACS staining
profiles of progenitor populations. (B) Percentages of each progenitor populations (GMP,
CMP and MEP) relative to total GFP positive cells. Values were derived from 4 mice per
group, and represented as averages. Data shows statistical significance of total progenitor
population relative to p210 (* p < 0.05, ** p < 0.01, *** p < 0.001). (C) Survival curves of
secondary transplanted mice. A total of 1×106 cells (bone marrow and spleen) isolated from
diseased mice were injected into sublethally irradiated BALB/c mice. When comparing
p210 BCR/ABL with p210 BCR/ABL(S509A) a Mantel-Cox test for the survival curves
yielded a value of p = 0.004 (χ2 = 8.28).
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Table 1
Comparison of WBC counts, spleen weight, blasts and lifespan
Mouse WBC (103/μl) spleen weight (g) % blasts lifespan (day)
Vector1 5.77±0.94 0.096±0.008 0 NA
p210 BCR/ABL 118.5±31.94 0.878±0.098 26.4±5.88 28 (23–38)
p190 BCR/ABL 34.97±33.02 0.438±0.067 83.2±4.35 16 (15–21)
p210 BCR/ABL(S509A) 39.74±25.11 0.737±0.123 82.1±5.73 16 (15–17)
Data shown is for a minimum of 5 mice per group.
For lifespan, the range of ages at death is shown in parentheses.
% blasts = percentage of blasts in peripheral blood as assessed by morphology.
1
Indicates mice that were electively sacrificed. All other mice succumbed due to disease.
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Table 3
Analysis of erythroid dysplasia at death
Mouse nRBC/100 WBC % reticulocytes RBC (106/(μl) Hemoglobin, g/dl % hematocrit CD71+/Ter119+
% of total cells
Vector1 0 3.81±1.9 8.75±0.26 13.92±0.44 43.9±1.57 13.33±1.52
p210 BCR/ABL 2.85±2.85 14.39±4.61 9.65±1.47 16.36±2.37 52.70±8.31 30.33±2.3
p190 BCR/ABL 222.9±154.6 24.71±8.27 8.20±0.69 13.43±1.22 43.97±4.36 71.67±5.77
p210 BCR/ABL (S509A) 145.6±140.1 28.59±6.74 9.93±0.91 14.86±1.37 47.33±4.37 73.67±4.93
Data shown is for a minimum of 5 mice per group.
nRBC = nucleated red blood cells. WBC = white blood cells. RBC = red blood cells. Total cells = total mononuclear cells analyzed.
1
Indicates mice that were electively sacrificed. All other mice succumbed due to disease.
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Table 4
Analysis of CD117 expression at death
Mouse
Peripheral blood % of Total Cells Bone marrow % of Total Cells Spleen % of Total Cells
GFP+ GFP+/CD117+ GFP+ GFP+/CD117+ GFP+ GFP+/CD117+
Vector a
#1 10 <1 10 2 4 <1
#2 20 <1 9 3 5 <1
#3 5 <1 7 2 4 <1
#4 9 <1 9 2 5 <1
p210 BCR/ABL
#1 83 2 81 3 65 7
#2 71 2 85 3 74 6
#3 71 1 81 3 53 3
#4 70 1 87 3 73 5
#5 75 2 87 4 52 4
p190 BCR/ABL
#1 45 43 47 46 58 50
#2 48 47 36 34 63 61
#3 68 66 54 53 68 65
#4 47 43 39 36 41 39
p210 BCR/ABL (S509A)
#1 44 43 64 62 63 59
#2 60 52 39 36 45 35
#3 41 30 45 44 37 31
#4 53 46 50 41 68 45
Total cells = total mononuclear cells analyzed. Red Blood Cell Lysis Buffer was used to remove red blood cells before analysis.
a
Indicates mice that were electively sacrificed. All other mice succumbed due to disease.
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